Influenza A Virus Inhibits Alveolar Fluid Clearance in BALB/c Mice
Proposed mechanism for inhibition of alveolar fluid clearance (AFC) after influenza A virus (IAV) infection of BALB/c mice. IAV infection results in increased release of the 5′-nucleotides, UTP and ATP, into the ALF. The UTP metabolite, UDP, activates P2Y6-subtype purinergic receptors, resulting in inhibition of amiloride-sensitive epithelial Na+ channels (ENaC) and reduced active Na+ absorption. Concurrently, released ATP is metabolized by 5′ ectonucleotidases to adenosine, which activates A1-subtype adenosine receptors (A1-AR) and thereby stimulates bronchoalveolar epithelial Cl− secretion via the CFTR. Together, reduced Na+ absorption and increased Cl− secretion result in severe impairment of AFC. Points of action of pharmacologic inhibitors used in the current study are also indicated: A77–1726 inhibits de novo pyrimidine synthesis; fluoxetine and ROCKi block opening of volume-regulated ion channels, which are the proposed release pathway for UTP; apyrase and UDP-glucose pyrophosphorylase (UDP-G-PP) prevent formation of UDP from UTP (by promoting formation of UMP and UDP-glucose from UTP, respectively); suramin and XAMR-0721 are P2Y purinergic receptor antagonists; amiloride inhibits ENaC activity; metADO inhibits 5′ ectonucleotidase–mediated hydrolysis of ATP to adenosine; 8-SPT and DCPCX are A1-adenosine receptor antagonists; CFTRinh-172 and glibenclamide are CFTR Cl− channel blockers.